Investors
Find out more about our business and financial information.
Investment story
Cereno Scientific is a pioneering clinical-stage biotech company focusing on developing innovative, effective, and safe treatments for patients affected by rare and common cardiovascular disease where great unmet medical needs persist. Cardiovascular disease is the number one cause of death globally, killing nearly twice as many people as cancer. The term cardiovascular disease includes all diseases which involve the heart and/or the blood vessels. A majority of the complications associated with cardiovascular disease are caused by a blocking blood clot in a vein or artery in the body. Many people affected by a blood clot have as a consequence, for example, a heart attack, secondary heart failure, cardiac arrhythmias, stroke or other direct manifestations of blood clots in lungs or peripheral vessels.
Cereno's pipeline comprises:
- Drug candidate CS1, a HDAC inhibitor with epigenetic modulation effects, in Phase II is being developed as a treatment of the rare disease pulmonary arterial hypertension (PAH).
- Drug candidate CS014, a novel HDAC inhibitor with epigenetic modulation effects, in late preclinical phase is being developed as a treatment for thrombosis prevention.
- Drug candidate CS585, a novel IP Receptor Agonist, in preclinical phase is being evaluated as a treatment for cardiovascular disease.
Cereno Scientific's B share (CRNO B) has been traded on Nasdaq First North Growth Market since June 2023, when a move from Spotlight Stock Market was completed where the company had been listed since June 2016.
Share capital development
Overview
Shares of series A warrant ten (10) votes per one (1) share and shares of series B warrant one (1) vote per one (1) share. The shares ratio value amounts to 0,1 SEK. All shares entitle the shareholder to equal rights to share the company’s assets and earnings.
Updated: December 2020
Year | Event | Ratio value (SEK) | Difference in shares | Change (SEK) | Total number of shares | Total share capital (SEK) |
---|---|---|---|---|---|---|
2012 | Formation | 1 | 50 000 | 50 000 | 50 000 | 50 000 |
2012 | Rights issue | 1 | 10 605 | 10 605 | 60 605 | 60 605 |
2016 | Directed issue | 1 | 1 200 | 1 200 | 61 805 | 61 805 |
2016 | Stock dividend issue | 10 | – | 556 245 | 61 805 | 618 050 |
2016 | Share split 100:1 | 0.1 | 6 118 695 | – | 6 180 500 | 618 050 |
2016 | Subdivision A-/B- shares | 0.10 | – | – | 6 180 500 | – |
2016 | Directed issue | 0.10 | 1 420 000 | 1 420 000 | 7 600 500 | 760 050 |
2016 | Directed issue | 0.10 | 450 000 | 45 000 | 8 050 500 | 805 050 |
2016 | IPO | 0.10 | 2 940 000 | 294 000 | 10 990 500 | 1 099 050 |
2018 | Conversion | 0.10 | 188 679 | 18 867.90 | 11 179 179 | 1 117 917.90 |
2018 | Conversion | 0.10 | 444 444 | 44 444.40 | 11 623 623 | 1 162 362.30 |
2018 | Conversion | 0.10 | 540 540 | 54 054 | 12 164 163 | 1 216 416.30 |
2018 | Conversion | 0.10 | 483 870 | 483 8700 | 12 648 033 | 1 264 803.30 |
2018 | Conversion | 0.10 | 419 354 | 41 935.40 | 13 067 387 | 1 306 738.70 |
2018 | Conversion | 0.10 | 384 614 | 38 461.40 | 13 452 001 | 1 345 200.10 |
2018 | Conversion | 0.10 | 269 230 | 26 923 | 13 721 231 | 1 372 123.10 |
2018 | Conversion | 0.10 | 307 692 | 30 769.20 | 14 028 923 | 1 402 892.30 |
2018 | Conversion | 0.10 | 333 333 | 33 333.30 | 14 362 256 | 1 436 225.60 |
2018 | Conversion | 0.10 | 285 714 | 28 571.40 | 14 647 970 | 1 464 797.00 |
2019 | Conversion | 0.10 | 533 333 | 53 333.30 | 15 181 303 | 1 518 130.30 |
2019 | Conversion | 0.10 | 666 666 | 66 666.60 | 15 847 969 | 1 584 796.90 |
2019 | Conversion | 0.10 | 3 333 333 | 333 333.30 | 19 181 302 | 1 918 130.20 |
2019 | Rights issue | 0.10 | 19 181 302 | 1 918 130.20 | 38 362 604 | 3 836 260.40 |
2019 | Overallotment issue | 0.10 | 1 724 137 | 172 413.70 | 40 086 741 | 4 008 674.10 |
2019 | Remuneration issue | 0.10 | 132 571 | 13 257.10 | 40 219 312 | 4 021 931.20 |
2020 | Rights issue | 0.1 | 31 600 000 | 3 160 000 | 71 819 312 | 7 181 931.20 |
2021 | Share issue | 0,10 | 33 442 470 | 3 344 247,00 | 105 261 782 | 10 526 178,20 |
Largest shareholders
Share issues
Our share issues
Access information related to the company’s current and/or previous share issues. Information is in Swedish only.
Analysts
Edison Investment Research
Analyst: Soo Romanoff
16 April 2024
Cereno Scientific — CS014 (thrombosis) progresses towards the clinic
Flash note
Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clinic with the submission of the clinical trial application (CTA) to the European Medicines Agency (EMA). The CTA is for the first-in-human Phase I trial for CS014, which Cereno is developing for thrombosis prevention, without increased risk of bleeding. We believe this has the potential to address the main limitation of current standard-of-care antithrombotic medicines and offers a sizeable opportunity for Cereno (backed by supportive preclinical data). Subject to clearance from the EMA, management plans to commence the Phase I study in Q224, consistent with prior guided timelines. Cereno’s lead asset is CS1, which is in a Phase II trial for pulmonary arterial hypertension (PAH). The results are expected in Q324, potentially representing the company’s next catalyst, in our view.
26 February 2024
Cereno Scientific – Executive interview with CSO and CMO
In this video, Soo Romanoff, healthcare managing director of Edison Group, interviews Bjorn Dahlof, CSO of Cereno Scientific, and CMO Rahul Agrawal, who discuss the company’s innovative product portfolio and targeting unmet needs in the cardiovascular diseases (CVD) space.
Cereno Scientific is a clinical-stage biotech focused on developing treatments for CVD using novel approaches. The company has an exciting pipeline of differentiated assets targeting unmet needs in CVD, with one clinical and two preclinical programmes. Lead candidate CS1 has an interesting mechanism of action (a histone deacetylase inhibitor (HDACi) showing epigenetic modulation properties) and promises disease-modifying properties in pulmonary arterial hypertension, a rare, debilitating and progressive condition with no curative therapies. With Phase II readouts expected in Q324, the company is approaching a significant period of inflection. The preclinical pipeline is led by CS014, a novel HDACi, initially targeting thrombosis (the leading cause of morbidity in CVD), but without increased risk of bleeding associated with currently available antithrombotics. With preclinical studies complete, the drug is set to enter the clinic in H124. The company’s other preclinical asset, CS585, is an IP agonist, currently under evaluation for different CVD indications, backed by encouraging preclinical evidence.
22 February 2024
Cereno Scientific – executive interview
In this video, Soo Romanoff, healthcare managing director of Edison Group, interviews Sten Sörensen, CEO of Cereno Scientific, who discusses the company’s innovative product portfolio, targeting unmet needs in the cardiovascular diseases (CVD) space, and the key upcoming catalysts.
Cereno Scientific is a clinical-stage biotech focused on developing treatments for CVD using novel approaches. The company has an exciting pipeline of differentiated assets targeting unmet needs in CVD, with one clinical and two preclinical programmes. Lead candidate CS1 has an interesting mechanism of action (a histone deacetylase inhibitor (HDACi) showing epigenetic modulation properties) and promises disease-modifying properties in pulmonary arterial hypertension, a rare, debilitating and progressive condition with no curative therapies. With Phase II readouts expected in Q324, the company is approaching a significant period of inflection. The preclinical pipeline is led by CS014, a novel HDACi, initially targeting thrombosis (the leading cause of morbidity in CVD), but without increased risk of bleeding associated with currently available antithrombotics. With preclinical studies complete, the drug is set to enter the clinic in H124. The company’s other preclinical asset, CS585, is an IP agonist, currently under evaluation for different CVD indications, backed by encouraging preclinical evidence.
22 February 2024
Cereno Scientific — Differentiated approach in CVD with potential
Initiation
Cereno Scientific is a clinical-stage biotech, developing treatments for cardiovascular diseases (CVDs) using novel approaches. Its focus on disease-modifying therapies and a collaboration with Abbott set it apart from peers. Lead asset CS1, a delayed immediate release formulation of VPA, is an HDAC inhibitor, aiming to deliver disease-modifying results in pulmonary arterial hypertension (PAH). Preclinical candidates include CS014, for thrombosis prevention without increased risk of bleeding (seen with current antithrombotics), and CS585 for CVD (specific indication not yet determined). 2024 will be a period of inflection, with top-line readouts from the Phase II CS1 study and expected clinical entry of CS014. We initiate coverage with a valuation of SEK2.32bn (SEK9.9/share).
Financial reports
2023
26 March 2024
22 February 2024
17 November 2023
25 August 2023
22 May 2023
2022
6 April 2023
22 Feb 2023
16 Nov 2022
25 Aug 2022
19 May 2022
2021
6 Apr 2022
9 Feb 2022
16 Nov 2021
25 Aug 2021
19 May 2021
2020
5 May 2021
25 February 2021
Year-end report (Q4) 2020
19 November 2020
28 Aug 2020
14 May 2020
2019
14 May 2020
27 February 2020
14 November 2019
30 August 2019
30 April 2019
2018
30 April 2019
22 February 2019
15 November 2018
30 August 2018
24 May 2018
2017
9 May 2018
2016
22 May 2017
Financial calendar
22 May 2023
Interim report Q1 2023
1 June 2023
Annual General Meeting
25 August 2023
Interim report Q2 2023
17 November 2023
Interim report Q3 2023
22 February 2024
Interim report Q4 2023
26 March 2024
Annual Report 2023
23 May 2024
Interim report Q1 2024
16 April 2024
Annual General Meeting 2024
29 August 2024
Interim report Q2 2024
21 November 2024
Interim report Q3 2024
25 February 2025